An open label phase II trial of glufosfamide: A β-D-glucose-linked isophosphoramide mustard given as 1-hour infusion in patients with advanced breast cancer This is an ASCO Meeting Abstract from the ...

Treatment cuts risk of death and recurrence, but some women still go without. July 29, 2011— -- For women diagnosed with hormone-sensitive breast cancer-- more than 150,000 in the U.S. each year- ...

Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables PURPOSE: To identify predictors of ...

May 2, 2003 — A retrospective cohort study reported in the April issue of the World Journal of Surgery showed a significant association between gallstones and the use of tamoxifen. "Despite tamoxifen ...

Studying the possible association between AI and cognitive dysfunction has accelerated over the past 7 years. A pilot study using neuropsychological testing from the Arimidex, Tamoxifen, Alone or in ...

A new study has shown that variation in the microbiota of the human gut impacts the pharmacokinetics of tamoxifen and thus the effectiveness of the drug. The finding, published in the journal mBio of ...

Please provide your email address to receive an email when new articles are posted on . Patients with DCIS who received tamoxifen had a lower 15-year risk for ipsilateral breast cancer recurrence.

Tamoxifen is a common and important treatment to prevent breast cancer from recurring. A new study shows that variation in a patient's gut microbiome can impact how effective the treatment is. A new ...